Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report

Kucharz,Jakub; Michalowska‑Kaczmarczyk,Anna; Zygulska,Aneta L.; Wojtak,Jolanta; Pawlik,Wieslaw; Herman,Roman   M.; Krzemieniecki,Krzysztof

doi:10.3892/ol.2016.4195

March-2016 Volume 11 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2016 Volume 11 Issue 3

Full Size Image

Case Report

Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report

Authors:
- Jakub Kucharz
- Anna Michalowska‑Kaczmarczyk
- Aneta L. Zygulska
- Jolanta Wojtak
- Wieslaw Pawlik
- Roman M. Herman
- Krzysztof Krzemieniecki
View Affiliations / Copyright

Affiliations: Department of Oncology, University Hospital in Kraków, Kraków 31‑531, Poland, Section of Computed Tomography, Second Department of Internal Medicine, University Hospital in Kraków, Kraków 31‑066, Poland, Department of Experimental and Clinical Surgery, Jagiellonian University Medical College, Kraków 31‑126, Poland
Pages: 2297-2299
|
Published online on: February 8, 2016

https://doi.org/10.3892/ol.2016.4195
Expand metrics +

Abstract

Cisplatin (DDP) is one of the most frequently used chemotherapeutic agents, and has a characteristic toxicity profile. For DDP, complications affecting the cardiovascular system, which are typical for certain other agents, are rare; however, their occurrence may lead to life‑threatening conditions. To the best of our knowledge, there are few reported cases of DDP‑induced bradycardia in the relevant medical literature. The current report presents the case of a 58-year-old patient diagnosed with metastatic neuroendocrine carcinoma with a primary lesion in the posterior mediastinum, who was treated with DDP and etoposide chemotherapy. Following the initial chemotherapy cycle, the patient experienced severe symptomatic bradycardia (a drop in heart rate to 40 bpm), with the corrected QT interval prolonged to 424 msec. The patient's condition required close monitoring and treatment. Similar symptoms occurred following each of the three cycles of chemotherapy. Imaging studies performed following the third treatment cycle revealed disease progression, and the patient was referred for palliative care. Reports have indicated that damage to the cardiovascular system, including cardiac ischemia, diastolic disturbances, hypertension and microalbuminuria, may be associated with DDP‑based therapy. However, the mechanism of DDP‑associated cardiac toxicity remains to be elucidated. It may be induced by factors including direct toxicity, ion imbalance, heart infiltration and, in the case of neuroendocrine tumors, the influence of tumor excretions.

View Figures

View References

1	Prestayko AW, D'Aoust JC, Issell BF and Crooke ST: Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 6:17–39. 1979. View Article : Google Scholar : PubMed/NCBI
2	Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med. 100:704–713. 1984. View Article : Google Scholar : PubMed/NCBI
3	Bovelli D, Plataniotis G and Roila F: ESMO Guidelines Working Group: Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 21(Suppl 5): v277–v282. 2010. View Article : Google Scholar : PubMed/NCBI
4	Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA and Ewer MS: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation. 109:3122–3131. 2004. View Article : Google Scholar : PubMed/NCBI
5	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
6	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
7	Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 18:1725–1732. 2000.PubMed/NCBI
8	Tassinari D, Sartori S, Drudi G, Panzini I, Gianni L, Pasquini E, Abbisciano V, Ravaioli A and Iorio D: Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature. Ann Oncol. 8:1263–1267. 1997. View Article : Google Scholar : PubMed/NCBI
9	Schlaeffer F, Tovi F and Leiberman A: Cisplatin-induced bradycardia. Drug Intell Clin Pharm. 17:899–901. 1983.PubMed/NCBI
10	Altundağ O, Celik I and Kars A: Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann Pharmacother. 35:641–642. 2001. View Article : Google Scholar : PubMed/NCBI
11	Blachley JD and Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med. 95:628–632. 1981. View Article : Google Scholar : PubMed/NCBI
12	Maier HC and Sommers SC: Neuroendocrine carcinoma of lung associated with bradycardia and episodic cardiac asystole. Ann Thorac Surg. 41:560–562. 1986. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles